COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges

Moubarak, Simon; Merheb, Diala; Basbous, Lynn; Chamseddine, Nabil; Zerdan, Maroun Bou; Assi, Hazem

doi:10.1177/03000605221125047

Cited by 10 publications

(7 citation statements)

References 88 publications

(195 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is nowadays one of the most common and fatal cancer and lobectomy is the treatment of choice for its curative intent [ 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ]. Video-assisted thoracoscopic surgery (VATS) is currently the preferred technique for pulmonary lobectomy, being minimally invasive compared to open lobectomy.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

et al. 2023

View full text Add to dashboard Cite

Background: The COVID-19 outbreak had a massive impact on lung cancer patients with the rise in the incidence and mortality of lung cancer. Methods: We evaluated whether a recent COVID-19 infection affected the outcome of patients undergoing thoracoscopic lobectomy for lung cancer using a retrospective observational mono-centric study conducted between January 2020 and August 2022. Postoperative complications and 90-day mortality were reported. We compared lung cancer patients with a recent history of COVID-19 infection prior to thoracoscopic lobectomy to those without recent COVID-19 infection. Univariable and multivariable analyses were performed. Results: One hundred and fifty-three consecutive lung cancer patients were enrolled. Of these 30 (19%), had a history of recent COVID-19 infection prior to surgery. COVID-19 was not associated with a higher complication rate or 90-day mortality. Patients with recent COVID-19 infection had more frequent pleural adhesions (p = 0.006). There were no differences between groups regarding postoperative complications, conversion, drain removal time, total drainage output, and length of hospital stay. Conclusions: COVID-19 infection did not affect the outcomes of thoracoscopic lobectomy for lung cancer. The treatment of these patients should not be delayed in case of recent COVID-19 infection and should not differ from that of the general population.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[33][34][35] The declaration of a global pandemic by the World Health Organization (WHO) in March 2020 led to a drastic decrease in health care delivery and screening worldwide. [36][37][38][39][40] Although previous research has assessed the impact of the COVID-19 pandemic on screening for other cancers, the effect of lockdown restrictions on CRC screening volumes, especially among vulnerable populations, remains ill-defined. 13,36 The current study was important because we specifically characterized the decline in CRC screening during the pandemic, as well as the subsequent recovery in screening volumes relative to county-level SVI and race/ethnicity in a nationally representative cohort.…”

Section: Discussionmentioning

confidence: 99%

Association of COVID-19 Pandemic with Colorectal Cancer Screening: Impact of Race/Ethnicity and Social Vulnerability

Khan,

Munir,

Woldesenbet

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Background The COVID-19 pandemic disrupted health care delivery, including cancer screening practices. This study sought to determine the impact of the COVID-19 pandemic lockdown on colorectal cancer (CRC) screening relative to social vulnerability. Methods Using the Medicare Standard Analytic File, individuals 65 years old or older who were eligible for guideline-concordant CRC screening between 2019 and 2021 were identified. These data were merged with the Center for Disease Control Social Vulnerability Index (SVI) dataset. Changes in county-level monthly screening volumes relative to the start of the COVID-19 pandemic (March 2020) and easing of restrictions (March 2021) were assessed relative to SVI. Results Among 10,503,180 individuals continuously enrolled in Medicare with no prior diagnosis of CRC, 1,362,457 (12.97%) underwent CRC screening between 2019 and 2021. With the COVID-19 pandemic, CRC screening decreased markedly across the United States (median monthly screening: pre-pandemic [n = 76,444] vs pandemic era [n = 60,826]; median Δn = 15,618; p < 0.001). The 1-year post-pandemic overall CRC screening utilization generally rebounded to pre-COVID-19 levels (monthly median screening volumes: pandemic era [n = 60,826] vs post-pandemic [n = 74,170]; median Δn = 13,344; p < 0.001). Individuals residing in counties with the highest SVI experienced a larger decline in CRC screening odds than individuals residing in low-SVI counties (reference, low SVI: pre-pandemic high SVI [OR, 0.85] vs pandemic high SVI [OR, 0.81] vs post-pandemic high SVI [OR, 0.85]; all p < 0.001). Conclusions The COVID-19 pandemic was associated with a decrease in CRC screening volumes. Patients who resided in high social vulnerability areas experienced the greatest pandemic-related decline.

show abstract

“…Certainly, the reorganization of health structures has meant that in some contexts, just 10% of patients who needed ICU care were admitted for treatment [ 39 ]. Lung cancer patients have some special characteristics compared to other cancer patients: they often have comorbidities and pre-existing diseases, which may present increased risk of infection; but on the other hand, since the associated symptoms (such as cough, dyspnea, and hemoptysis) are the same as for COVID-19 [ 40 , 41 , 42 ], this increased the possibility of being subjected to radiological investigations even during the pandemic and discovering lung tumors [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

The Influence of COVID-19 on New Lung Cancer Diagnoses, by Stage and Treatment, in Northern Italy

Mangone

Marinelli

Bisceglia

et al. 2023

Biology

View full text Add to dashboard Cite

The COVID-19 pandemic has had a significant impact on new cancer diagnoses. This study aims to evaluate the implications of the lockdown period on new lung cancer diagnoses in northern Italy. We compared 2020 with 2019 cancer registry data, reporting the variations by age, stage, and treatments. In 2020, 303 lung cancer cases were registered, 21 fewer than in 2019. Cases fell in men (−31 patients, 9.6%) but not in women (+10 patients, +3.1%). A significant drop in stage I from 19.8% to 12.9% (p < 0.05) and an increase in stage III (12.7% vs. 19.1%; p < 0.05) was observed. Histological confirmation dropped (70.1% vs. 60.1%; p < 0.05) while cytology increased (12% vs. 20.8%; p < 0.01). Surgery declined (28.7% vs. 21.5%; p < 0.05) but increased in stage III (19.5% vs. 25.9%; p = 0.46), while chemotherapy increased (17.6% vs. 34.3%; p < 0.01) for all stages. During the pandemic, new lung cancer diagnoses dropped only in men. The reorganization of health services has ensured a decrease in surgical interventions (due to the unavailability of operating rooms) counterbalanced by an increase in chemotherapy.

show abstract

COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges

Cited by 10 publications

References 88 publications

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

Association of COVID-19 Pandemic with Colorectal Cancer Screening: Impact of Race/Ethnicity and Social Vulnerability

The Influence of COVID-19 on New Lung Cancer Diagnoses, by Stage and Treatment, in Northern Italy

Contact Info

Product

Resources

About